Navigation Links
Cell-based therapy shows promise in patients with Parkinson's disease
Date:4/28/2008

CHICAGO - A novel cell therapy using retinal pigment epithelial (RPE) cells attached to tiny gelatin bead microcarriers implanted in the brain can improve the symptoms of patients with moderate to advanced Parkinsons disease (PD).

Rush University Medical Center neurosurgeon Dr. Roy A. E. Bakay and colleagues from Emory University, Atlanta found the therapy Spheramine was well-tolerated and patients experienced improvement in Parkinsonian symptoms (tremor, rigidity, slowness of movements, and impaired balance and coordination.) These findings were presented at the Annual Meeting of the American Association of Neurological Surgeons in Chicago on April 28, 2008.

The pilot study was initiated at Emory University Hospital and followed six patients with moderate to advanced PD to investigate the safety, tolerability, and efficacy of the Spheramine implantation. The full patient group has been evaluated for four years, and several have been monitored for six years. Bakay and colleagues report long-term improvement or stabilization of symptoms, maintained for a minimum of two years after Spheramine implantation. They note no Spheramine-related serious adverse events were reported and that the most frequent adverse event was postsurgical headache, which spontaneously resolved within one to two weeks.

The results of this study are very encouraging Spheramine is well tolerated through several years of follow-up and improvement in parkinsonian symptoms is sustained, stated Bakay.

The cellular product Spheramine consists of RPE cells attached to microcarriers. RPE cells produce levodopa, the precursor of dopamine. Dopamine is a neurotransmitter produced by nerve cells in the brain that progressively declines as the disease progresses.

The RPE cells, which are normally found in the back of the eye, are cultured under standardized conditions and attached to the microscopic beads prior to implantation. The microcarriers are necess
'/>"/>

Contact: Mary Ann Schultz
mary_ann_schultz@rush.edu
312-933-7333
Rush University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Challenges and promise of cell-based therapies
2. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
3. A new radiation therapy treatment developed for head and neck cancer patients
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. UC health news: molecular pathway may predict chemotherapy effectiveness
6. MIT works toward safer gene therapy
7. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
8. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
9. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
10. Safe and effective therapy discovered for patients with protein-losing enteropathy
11. Ireland Cancer Center researchers advance stem cell gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Evergreen State College currently advises a team of ... prison-issued garb rather than the lab coats and ... team composed of such apparently iconoclastic researchers? Because ... Creek Corrections Center, a medium security prison in ...
... Reducing the number of deer in forests and ... and insects in that area, new research suggests. ... University and National Park Service found that higher deer ... of several species of snakes, salamanders, and invertebrates studied, ...
... 2008 -- The widespread use of pesticides across the United ... of the long-term effects on the nation,s groundwater. ... taken from over 300 wells across the US have not ... a result of a decadal long study to assess the ...
Cached Biology News:Inmates conduct ecological research on slow-growing mosses 2Snakes, salamanders and other creatures thrive in areas with higher deer populations 2Snakes, salamanders and other creatures thrive in areas with higher deer populations 3Pesticide concentrations decreasing 2
(Date:1/22/2015)... January 22, 2015 Eckert & Ziegler ... Spectrometry (AMS) services to the pharmaceutical and biotech industry, ... the company in the position of Director of Science ... broad and valuable experience in drug metabolism and bioanalysis ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... CO / Rootstown, OH (PRWEB) January 22, 2015 ... detection platform, announced today that it has received AOAC-PTM Certifications ... O45, O1O3, O111, O121, and O145; collectively referred to as ... coli) O157, at 1 colony forming unit (cfu) per 325 ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2
... Inc. (Nasdaq: IDEV ) today announced that ... Food and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a ... only product approved by the FDA for therapy ... the,urinary bladder. VALSTAR was removed from the ...
... Extracranial Resources Benefits Baltimore ... Area and ... Cancer Center at Johns Hopkins Medicine is adding an Elekta,Synergy(R) S ... Johns Hopkins aims to fight cancer with,both intracranial and extracranial resources ...
... Balance of Year, SAN DIEGO, Aug. 17 ... Noble Financial Equity,Conference at 11:30 a.m. EDT on Tuesday, ... South Carolina. William Spencer, Imagenetix,s Chief Executive Officer ... and prospects for the,Company. Commenting on the prospects, Mr. ...
Cached Biology Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 2Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 3Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007 2
Component in MasterPure™ Purification Kits...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Mouse anti-Insulin-Like-3 Class: Antibody Product Group: Adipokine and Obesity related...
Biology Products: